Related by context. All words. (Click for frequent words.) 65 Pharmacokinetic parameters 64 calculated creatinine clearance 64 azilsartan medoxomil 63 pharmacodynamic parameters 63 thorough QT 63 Ambulatory Blood Pressure 62 polysomnography PSG 62 teriflunomide 62 HCV RESPOND 2 62 RECORD1 62 Tumor Response 62 pharmacodynamic effects 61 GAMMAGARD 61 Carotid Revascularization Endarterectomy vs. 61 AVERROES 61 epoetin alpha 61 Tasigna prolongs 61 GSK# [002] 61 Mg Usa 60 blinded randomized placebo controlled 60 biostatistical analysis 60 ARB telmisartan 60 Pharmacodynamic 60 EMPHASIS HF trial 60 EURIDIS 60 phase IIIb 60 Pharmacokinetic 60 serum phosphorous 60 statin monotherapy 60 recombinant PSMA vaccine 60 oral rivaroxaban 60 HCV SPRINT 60 Skin sterol 60 REVIVE TA 60 randomized multicenter trial 60 pharmacokinetic characteristics 60 Primary endpoints 59 transcranial Doppler ultrasound 59 prospective multicentre 59 STRIDE PD 59 CELVAPAN H#N# 59 Myocardial Perfusion Imaging 59 dose escalation phase 59 intermittent dosing 59 IMPACT DCM 59 CARE HF 59 meta regression 59 multicenter randomized controlled 59 bevirimat Study 59 hemoglobin A1C HbA1C 59 glycosylated hemoglobin HbA1c 59 multicenter Phase II 59 riociguat 59 prospective observational studies 59 electrophysiologic 59 ExTRACT TIMI 59 Blood Pressure Measurement 59 See CLINICAL PHARMACOLOGY 59 EXPLORE Xa 59 designated HVTN 59 intradermal injections 59 number NCT# ClinicalTrials.gov 59 Meta analyzes 59 CHAMPION PCI 59 placebo controlled multicenter 59 RE LY ® 59 relapsed MM 59 Val HeFT 59 Screening Trial 58 prospective observational cohort 58 Randomized controlled 58 BRIM3 58 subanalysis 58 HORIZONS AMI trial 58 NSABP B 58 CLARITY study 58 PRIMO CABG 58 treatment naive genotype 58 bepotastine besilate nasal spray 58 pressure monitoring ABPM 58 microalbumin 58 fidaxomicin Phase 58 QT QTc 58 TAXUS ARRIVE 58 9mg 58 PRIMO CABG2 58 ORAL Sync 58 Multivariate logistic regression 58 postintervention 58 Sorafenib HCC Assessment 58 MEND CABG 58 MAGE A3 ASCI 58 Echocardiographic 58 urine albumin 58 Xelox 58 ABSORB trial 58 polysomnogram 58 PERSEUS 58 pharmacokinetic pharmacodynamic 58 CALERIE 58 TRA 2P 58 midstage clinical 58 pioglitazone hydrochloride 58 Stenting Trial CREST 58 confirmatory clinical 58 insulin glulisine 58 PCI ExTRACT TIMI 58 abacavir lamivudine 58 Lipitor #mg 58 ENDEAVOR III 58 enzyme immunoassay EIA 58 Cardiotoxicity 58 galiximab 58 Oral NKTR 58 vitro dissolution 58 multicenter Phase III 58 mg kg BID 58 ug kg 58 phase IIb study 58 pivotal bioequivalence 57 Sibutramine Cardiovascular Outcomes 57 albiglutide 57 Cardiorespiratory fitness 57 Creatinine 57 randomized controlled multicenter 57 Maximum Tolerated Dose MTD 57 BoNTA 57 Mg Uk 57 urodynamic 57 antidepressants fluoxetine 57 Spirometry 57 ToGA 57 6mg 57 CUSTOM III 57 NNT = 57 viral kinetics 57 glulisine 57 CAMMS# 57 SUTENT ® 57 Neupro R 57 Phase IIB 57 hematologic parameters 57 #mg/day [001] 57 AST ALT 57 ACCORD Lipid 57 SIMPADICO 57 XL# SAR# 57 PSMA ADC 57 exhaled NO 57 Pharmacokinetic PK 57 investigational protease inhibitor 57 Forodesine HCl 57 Phase III ADT 57 phase Ib 57 PreCISe 57 atorvastatin #mg 57 NO# [002] 57 diuretics beta blockers 57 aspartate aminotransferase AST 57 reduce serum phosphate 57 metabolite concentrations 57 Onglyza saxagliptin 57 phase IIa 57 placebo controlled Phase 57 Subgroup analysis 57 Prostate AdenoCarcinoma Treatment 57 BRIM2 57 Phase IIb III 57 Celecoxib APC trial 57 multicenter randomized clinical 57 ginkgo extract 57 amphetamine methamphetamine 57 RE LY 57 YONDELIS 57 Anturol TM 56 R# #mg BID 56 preclinical efficacy 56 Abdominal ultrasound 56 NIASPAN 56 clinical pharmacology studies 56 Vaccine Immunology 56 Univariate 56 trials RCTs 56 ASSERT trial 56 ancrod 56 Symptom severity 56 IEQ kg 56 Flow cytometry 56 microdose 56 Oral Fingolimod 56 brivaracetam 56 #mg doses [002] 56 d dimer 56 VADT 56 postdose 56 hemoglobin A1c HbA1c 56 ENDEAVOR IV 56 pravastatin Pravachol 56 randomized controlled Phase 56 Cervista HPV HR 56 racemic albuterol 56 EmbraceAC 56 brachial artery flow 56 Randomized Evaluation 56 Afatinib 56 Ramelteon 56 Active Ulcerative Colitis 56 fosbretabulin 56 hemostatic efficacy 56 Peptide YY 56 maximally tolerated dose 56 platelet aggregation inhibitors 56 fasting plasma glucose FPG 56 deCODE AF TM 56 hemodynamic variables 56 paricalcitol 56 pharmacokinetic PK 56 methacholine challenge 56 bezafibrate 56 fasting serum 56 subcutaneous PRO 56 cannabinor 56 Non inferiority 56 #mg dose [002] 56 Zemplar Capsules 56 Bacteriological 56 #mg #mg #mg [003] 56 Dialysis Outcomes 56 spirometric 56 inhalations twice 56 BEZ# 56 Decompensated Heart Failure 56 lomitapide 56 logistic regression models 56 PRADAXA #mg 56 preclinical pharmacokinetic 56 dose titration 56 Alteplase 56 GISSI 56 multicentre randomized 56 anastrazole 56 specified secondary endpoints 56 BARI 2D 56 GSK# [001] 56 opioid naive 56 edifoligide 56 Phase III VISTA 56 nucleotide analogue 56 multicenter phase 56 budesonide foam 56 Visual Analogue Scale VAS 56 Phase IIA 56 Adverse Event 56 urinary sodium excretion 56 Exploratory IND 56 ERBITUX infusion 56 ascending dose 56 aldosterone antagonist 56 randomized multicenter Phase III 56 Platelet Inhibition 56 Bioequivalence 56 reactogenicity 56 rt PA 56 Phase Ib clinical 56 APPRAISE 56 bronchial lavage 56 Cochrane Systematic Review 56 certolizumab 56 bioequivalency 56 Warfarin Coumadin 56 1mg 2mg 56 serum potassium 55 polysomnographic 55 Bayer HealthCare Onyx Pharmaceuticals 55 5mg/kg 55 multicentre prospective 55 Randomized Double blind 55 By JENNIFER LEARN 55 TAXUS ATLAS 55 MERIT ES 55 oral antidiabetes 55 maximal doses 55 Paliperidone ER 55 Prospective Randomized 55 intravenous dosing 55 trastuzumab emtansine T DM1 55 phase IIb trial 55 ANCHOR trial 55 canagliflozin 55 Liver biopsies 55 myocardial uptake 55 Bare Metal Stent 55 culture supernatants 55 Androgel R 55 AVADO 55 Initiated Phase 55 Techni lab 55 HER2 expression 55 Plasma concentrations 55 registrational Phase 55 ORMD 55 retest reliability 55 Nymox NX 55 ORAL Solo 55 antiepileptics 55 Cholestech LDX R 55 Phase IIIb 55 multidose 55 Erythropoiesis Stimulating Agents ESAs 55 NATRECOR ® 55 CALGB # [002] 55 orally inhaled 55 IV bolus 55 Intervention Trial GAIT 55 perfusion MRI 55 nonrandomized 55 beta2 agonist 55 ENESTnd 55 PROactive study 55 NSABP C 55 Phase IIIb clinical 55 multiple logistic regression 55 Schizophrenia Treatment 55 retrospective observational study 55 SYMMETRY trial 55 QTc prolongation 55 human Chorionic Gonadotropin 55 mm Hg diastolic 55 glucose insulin 55 RIO Lipids 55 Phase Ib II 55 Edge STudy 55 vivo preclinical 55 serum leptin 55 Avandia Actos 55 AMPAKINE CX# 55 SABCS 55 CPAP adherence 55 exhaled nitric oxide 55 ENGAGE AF TIMI 55 intima media thickness IMT 55 Corus CAD 55 Darapladib 55 Electrophysiological 55 DASISION 55 genotypic resistance 55 crizotinib PF # 55 Phase 1a clinical 55 dose escalation clinical 55 TriGrid 55 CYP#A# substrate 55 hyperinsulinemic euglycemic clamp 55 OGTT 55 serum electrolytes 55 budesonide pMDI 55 EDARBI 55 PORxin TM platforms 55 Phase III multicenter 55 AERx ® 55 Secondary efficacy endpoints 55 Refractory Angina 55 raloxifene Evista 55 5 Fluorouracil 55 semiquantitative 55 CT perfusion 55 glomerular filtration rate 55 administered intramuscularly 55 serum cortisol 55 PhG alpha 1 55 nonfasting 55 WHIMS 55 randomized controlled trials RCTs 55 specified primary endpoint 55 UKPDS 55 #rd Annual CTRC 55 mild hepatic impairment 55 Treatment Outcome 55 Cervical Cytology 55 hemoglobin A1C 54 Subgroup analyzes 54 Randomized Controlled Trials 54 Phase 1b clinical trials 54 ABCSG 54 intravenous tPA 54 MiDAS 54 Phase Ib study 54 creatinine clearance 54 DAVANAT R exhibits 54 cardiac troponin T 54 phase IIa clinical 54 paracentesis 54 glomerular filtration 54 CATIE AD 54 preintervention 54 NCT# ClinicalTrials.gov 54 RIO Diabetes 54 cardiac repolarization 54 glycated hemoglobin levels 54 Thorough QT 54 symptomatic VTE 54 nicardipine 54 Indacaterol 54 coronary stenosis 54 recurrent glioma 54 TQT studies 54 buccal spray 54 active comparator 54 Cardiac Resynchronization 54 selenium supplementation 54 Epidemiological Studies Unit 54 fidaxomicin Phase 3 54 Women Ischemia Syndrome 54 chest radiographs 54 maximal dose 54 Grouped Hockey 54 LungAlert TM 54 Hematocrit 54 dacarbazine chemotherapy 54 IIa clinical 54 LUMINATE 54 Nicotine Vaccine 54 statins cholesterol lowering 54 Sentinel Lymph Node 54 novel VDA molecule 54 Quantitation 54 docetaxel Taxotere ® 54 morphine fentanyl 54 mcg doses 54 Clinical Evaluation 54 metabolic parameters 54 Intravenous immunoglobulin 54 pharmacokinetic PK study 54 GRAVITAS trial 54 GetGoal Phase III 54 fluticasone furoate 54 esophageal manometry 54 Neuropsychiatric Inventory NPI 54 Phase III placebo controlled 54 Pharmacodynamics 54 either acutely decompensated 54 Urinalysis 54 eosinophilic asthma 54 PREVENT IV 54 prospective nonrandomized 54 intravesical infusion therapy 54 pyrimidine nucleoside analog 54 lipid parameters 54 microalbumin test 54 #.#/#.# mmHg [001] 54 dosage regimens 54 aminotransferase ALT 54 albumin excretion rate 54 eNO 54 element ICP MS 54 MGN# 54 #th Annual Interscience 54 IMPROVE IT 54 Accelerated Partial Breast Irradiation 54 including eniluracil ADH 54 Confirmatory testing 54 CLIRS 54 combines bupropion 54 PEARL SC 54 Liraglutide Effect 54 SPIRIT FIRST 54 Fasting glucose 54 posttest 54 mg administered orally 54 eFlow R 54 underwent coronary angiography 54 bronchial hyperresponsiveness 54 chronic thromboembolic pulmonary 54 cyclosporine tacrolimus 54 postprocedure 54 Scintigraphy 54 pelvic ultrasound 54 urinary N telopeptide 54 evaluating satraplatin plus 54 QTcF 54 olanzapine LAI 54 ongoing Phase 1b 54 acyclovir Lauriad R 54 skin sterol 54 Jack Pirozzolo 54 Toxicological 54 alfuzosin 54 CINQUIL 54 barbiturates benzodiazepines 54 Vasotrac 54 preclinical pharmacology 54 Histologic 54 pharmacologic stress 54 bolus dose 54 Kamada AAT 54 ONTARGET 54 LCP AtorFen 54 subchronic 54 cromolyn sodium 54 mL vials 54 tesofensine 54 #mg dose [001] 54 #mg doses [001] 54 mg kg hr 54 randomized crossover 54 Phase #/#a 54 visilizumab 54 prospective randomized multicenter 54 Vaxfectin TM 54 hepatorenal syndrome 54 Complications Trial 54 DEB# 54 mL/min/#.# m 2 54 Postoperative complications 54 echocardiographic parameters 54 #mg dose [003] 54 Perforomist ™ Inhalation Solution 54 DAPT 54 elective PCI 54 Combination REOLYSIN R 54 zoledronate 54 Dr. Gabriel Lasala 54 Temsirolimus 54 PROTECT AF 54 glycated hemoglobin HbA1c 54 transient elastography 54 coronary arteriography 54 Severity MSCS score 54 triple nucleoside regimen 54 serum lipid 54 CLARITY TIMI 54 statistically significant efficacy 54 alicaforsen enema 54 Acute Stroke 54 Folfox 54 Blood Pressure Monitoring 54 Hsp# Inhibitor 54 mg kg Hematide 54 pediatric rehydration 54 ADVANCE PD 54 FDG-PET/CT 54 concentration Cmax 54 F FDG PET 54 morphometric vertebral fractures 54 REVIVE Diabetes 54 evaluating mipomersen 54 placebo controlled Phase III 54 journal Lancet Neurology 54 Daptomycin 54 Crohn Disease Activity 54 Hormone Refractory Prostate Cancer 54 INVEGA ® 54 multicenter prospective 54 Confirmatory 54 Aggressive Reduction 54 anti Parkinsonian 54 colonoscopy flexible sigmoidoscopy 54 macrolide antibiotic 54 Fasting plasma glucose 54 salmeterol fluticasone 54 Western Airborne Contaminants 54 Electroencephalography 54 STEP BD 54 budesonide MMX Phase III 54 Clinical Antipsychotic Trials 54 Protein Expression 54 Carotid Artery Stenting 54 cefotaxime 54 Outpatient Setting 54 ACOSOG Z# 54 assaying protocols 54 Randomized Phase II 54 transthoracic 54 dietary questionnaires 54 esophageal acid 54 ZOLINZA 54 ADCS ADL 54 NOAEL 54 phase IIb 54 aspirin clopidogrel 54 RSD# oral 54 Negative Symptoms 54 statistical significance p 54 EGS# 54 Cystatin C 54 DCE MRI 54 Phase IIIb study 54 folate vitamin B 54 serum bicarbonate 54 hemodynamic parameters 54 3mg/kg 54 Known hypersensitivity 54 midstage clinical trials 54 cobas e 54 LymphoStat B Phase 54 PERMP 54 Cholesterol Levels SPARCL 54 bronchoalveolar lavage 54 Clinical Psychopharmacology 54 RhuDex 54 Long Term Efficacy 54 OROS ® 53 #μg [001] 53 methylprednisolone steroid 53 mg eq 53 pharmacokinetic studies 53 demonstrated clinically meaningful 53 Multivariable logistic regression 53 hemagglutination inhibition HAI 53 intravenous iv 53 randomized controlled clinical trials 53 remifentanil 53 #mg ATC 53 buprenorphine naloxone 53 inflammatory biomarkers 53 MADIT CRT trial 53 mg RDEA# 53 Phase III Clinical Trials 53 Ranolazine 53 PLX STROKE targeting 53 SCIg 53 AOD# [002] 53 blood counts CBCs 53 multicenter multinational 53 Multiple logistic regression 53 suggest Roche Invirase 53 Medidur TM FA 53 mCi 53 eszopiclone 53 cTnT levels 53 lanthanum carbonate 53 aminotransferases 53 PROSTVAC TM 53 Cotinine 53 SPIRIT III 53 Coronary angiography 53 intramuscular dose 53 paroxetine Seroxat 53 MYTHOS trial 53 cediranib 53 NHAMCS 53 Bispectral Index 53 Captopril 53 intravascular hemolysis 53 olaparib 53 retrospective cohort 53 prospective randomized controlled 53 VKORC1 53 meta analysis pooling 53 NASA COBE satellite 53 neratinib 53 Corlux 53 subcutaneous enoxaparin 53 transdermal estradiol 53 creatinine levels 53 TMC# C# 53 left ventricular diastolic 53 mg/m2 cohort 53 genotoxicity reproductive toxicology 53 spiral computed tomography 53 ticagrelor Brilinta 53 MoxDuo ® IR 53 qualitative serum 53 HOMA IR 53 mg/# mL [002] 53 exploratory endpoints 53 Digoxin 53 folate vitamin B6 53 Prostate Specific Antigen PSA 53 bicifadine 53 esophageal pH 53 Clinical Outcome 53 VICTOR E1 53 Altera Nebulizer System 53 hemoglobin hematocrit 53 intraobserver 53 Commonly prescribed 53 Long Lesion 53 Vitro Diagnostic Device 53 Intervention Effectiveness CATIE 53 Intervention Effectiveness 53 myocardial infarct size 53 argatroban 53 CNS depressant 53 ToxCast ™ 53 Asthma Intervention 53 #.#mg 1mg 53 AIR CF2 53 random suspicionless employee 53 Pre RELAX AHF 53 Polysomnography 53 mean ± SEM 53 conditional logistic regression 53 Viral load 53 cotinine metabolite 53 bronchial reactivity 53 neutropenic sepsis 53 transesophageal echocardiography TEE 53 lovastatin Mevacor 53 system REG1 consists 53 pulmonary artery catheterization 53 logistic regression analyzes 53 DAS# CRP 53 NP2 Enkephalin 53 intravenous IV infusion 53 clomipramine 53 Ancrod 53 Am J Cardiol 53 Hemoglobin A1c 53 μg kg 53 placebo controlled clinical 53 formal pharmacokinetic PK 53 iPrEx 53 ENDEAVOR II 53 multicenter randomized placebo controlled 53 FDA Investigational Device 53 Blood Glucose Testing 53 treating enlarged prostates 53 ANCOVA 53 thyroid stimulating hormone TSH 53 overnight polysomnography 53 mild renal insufficiency 53 virological response 53 Aryplase 53 Inhaled Nitric Oxide 53 maternal serum 53 Digital Mammographic Imaging 53 assessing T DM1 53 triglyceride concentrations 53 urocortin 2 53 upper endoscopies 53 prospective multicenter study 53 transrectal ultrasound guided 53 viral kinetic 53 protein excretion 53 placebo controlled studies 53 Sanofi Pasteur Fluzone 53 plasma pharmacokinetics 53 Global Impression CGI 53 Cannabinor 53 oxycodone IR 53 serum aminotransferase levels 53 PREZISTA r 53 vecuronium 53 prolonged QT interval 53 Risk Stratification 53 midstage trials 53 plasma renin activity 53 Wechsler Adult 53 serum lipid levels 53 Urine tests 53 AIR CF1 53 CURRENT OASIS 7 53 HF ACTION 53 CrCl 53 PASI scores 53 TASKi2 53 #μg [002] 53 Novo TTF 53 blinded randomized controlled 53 NicAlert 53 PT INR 53 univariate 53 hyperphenylalaninemia HPA due 53 acute mania 53 antineoplastic 53 phase Ib clinical 53 ThermoDox ® clinical 53 Prostate Lung Colorectal 53 ACCLAIM II 53 Cervista HPV 53 glycoprotein IIb IIIa inhibitor 53 mL/min/#.# m2 53 cefazolin 53 miRview ™ squamous 53 salmeterol fluticasone propionate 53 mediated dilation 53 Edinburgh Postnatal Depression 53 Tranexamic acid 53 serum chemistries should 53 placebo controlled trials 53 myocardial revascularization 53 canakinumab 53 NeuroSTAT ® 53 multicenter Phase 53 plus Copegus R 53 Rigorous scientific 53 MVax 53 tuberculin skin tests 53 Topline Results 53 microarray experiments 53 Phase 1b trial 53 Persistent Sleep 53 clopidogrel pretreatment 53 AspirinWorks 53 oral deforolimus 53 dalteparin 53 Wisconsin Sleep Cohort 53 NovoLog ® Mix 53 EDEMA3 trial 53 Evaluation WISE 53 GnRH agonist 53 fructosamine 53 MF# adjuvanted vaccine 53 N telopeptide 53 glycosylated hemoglobin levels 53 multicenter placebo controlled 52 Transesophageal 52 AERAS-#/Crucell Ad# 52 intravenous cyclophosphamide 52 toxicological studies 52 darbepoetin alfa 52 salivary cortisol 52 Bone density 52 Ovarian Cancer Screening 52 identifier NCT# 52 bolus injection 52 cotinine byproduct 52 recombinant tissue plasminogen 52 Cytochrome P# 52 dual endothelin receptor antagonist 52 NSDUH 52 Clinical Trial Results 52 midazolam Versed 52 lactate dehydrogenase LDH 52 blinded randomized 52 intravenous tissue plasminogen 52 ISPO institute 52 binary logistic regression 52 TORISEL TM 52 Pivotal Clinical Trial 52 orofacial clefts 52 wrist actigraphy 52 buprenorphine implants 52 picogram 52 Roche AmpliChip 52 adenoma recurrence 52 posttreatment 52 Phase IIb clinical trials 52 Randomised 52 pyridostigmine 52 tramiprosate Alzhemed TM 52 ® darbepoetin alfa 52 Confirmatory tests 52 endoscopic gastric ulcers 52 recurrent venous thromboembolism 52 fasting triglycerides 52 radioimmunoassay 52 Carotid Endarterectomy 52 Breast Density 52 index assay IVDMIA 52 anaphylactic reactions bronchospasm 52 bupropion XL 52 angiographic outcomes 52 PLCO 52 requiring Asthmatx 52 Mussel Watch 52 Linear Array 52 beta blocker atenolol 52 prospective observational 52 neuropsychological assessments 52 AVN# Phase 52 warfarin dosage 52 Complex Frauds 52 IQ OQ PQ 52 hemoglobin A1c levels 52 Brief Psychiatric 52 Fasting blood glucose 52 dose cohorts 52 weekly intravenous infusions 52 total cholesterol triglycerides 52 anticoagulant warfarin 52 mL kg 52 inactivated strain 52 ConclusionThis 52 ADCS CGIC 52 Phase Ib Clinical Trial 52 Saquinavir 52 ViaDerm hPTH #-# 52 Population Enumeration 52 potassium sparing 52 CA9 SCAN 52 Clinical Guideline 52 Roche LightCycler ® 52 humanized therapeutic 52 Immunogenicity 52 alteplase 52 CRLX# 52 dosing cohorts 52 NOXAFIL Oral Suspension 52 ibuprofen acetaminophen 52 longitudinal cohort study 52 recurrent malignant glioma 52 telaprevir dosing 52 endoscopic retrograde cholangiopancreatography ERCGrant Parpan 52 Vertex hepatitis C 52 Sensitivity analyzes 52 LabCorp conducts clinical trials 52 ER CHOP 52 pegylated alpha interferon 52 Cytometry 52 EDEMA3 52 ONTARGET R 52 enzyme inhibition 52 Phase 1a 52 J Immunol 52 efavirenz EFV 52 mcg kg 52 pharmacodynamic markers 52 endocrinologic 52 optimal dosing 52 radiofrequency catheter ablation 52 randomized multicenter 52 glycated hemoglobin 52 pyrazinamide 52 AFREZZA Inhalation Powder 52 methylphenidate Ritalin 52 pharmacologically active isomer 52 Pooled Analysis 52 efficacy endpoint 52 Serological 52 metabolite identification 52 pharmacoeconomic analysis 52 urodynamic studies 52 fasting blood glucose 52 buproprion 52 Left Ventricular Dysfunction 52 parasitological 52 NicAlert ™ 52 D dimer 52 Hepatitis C Infection 52 corticosteroid dose 52 daily subcutaneous injections 52 nondiabetic subjects 52 FENO 52 #nd EORTC NCI 52 PC DAC Exendin 52 systemic hypotension 52 ularitide 52 pexelizumab trials 52 Prozac Paxil Zoloft Celexa 52 IRBS 52 mg simvastatin 52 Cryptographic Module Validation 52 eliglustat tartrate 52 Clinical Practice Guideline 52 biodistribution studies 52 Urgent Intervention Triage 52 Sentinel Lymph Node Biopsy 52 induced sputum 52 NADiA 52 mg/m2 administered 52 High Dose quadruples 52 Intervention Trial 52 NPH insulin 52 trastuzumab Herceptin ® 52 Phase Ib IIa 52 Alkaline Phosphatase 52 procalcitonin 52 candidates Dyloject TM 52 venous thromboembolic disease 52 Randomized Clinical Trials 52 Reduces Mortality 52 tiotropium Spiriva 52 Multivariate analysis 52 multivariate logistic regression 52 selective phosphodiesterase 52 oxymorphone IR 52 dose escalation trial 52 Arch Surg 52 VIVUS Qnexa 52 Immunomedics Announces 52 topically administered 52 Oral Glucose Tolerance 52 asymptomatic hyperuricemia 52 multicenter trials 52 dietary carbohydrate 52 Cholinesterase Inhibitors 52 NIHSS score 52 Mellaril 52 test OGTT 52 AdreView 52 double blinded randomized 52 topical calcineurin inhibitors 52 Patient Outcomes 52 Doppler echocardiography 52 FSH CTP 52 hydrochloric acid nitric acid 52 NAVISTAR R 52 sibutramine Meridia 52 Serum creatinine 52 via intradermal injections 52 total cholesterol LDL 52 hsCRP levels 52 Saxagliptin 52 Arch Neurol 52 Achieves Primary Endpoint 52 microgram kg 52 electrocardiogram EKG 52 laser Doppler